Overview

Monthly Dosing of Atacicept in IgAN

Status:
RECRUITING

Trial end date:
2027-09-01

Target enrollment:

Participant gender:

Summary

This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept

Phase:

PHASE2

Details

Lead Sponsor:

Vera Therapeutics, Inc.

Treatments:

TACI receptor-IgG Fc fragment fusion protein